Ozempic vs. Rybelsus nausea comparison: what week 4 vlogs miss

What did @pahndulce actually say?

She's four weeks into switching from Rybelsus (oral semaglutide) to the Ozempic subcutaneous pen, and she's noticing real differences. Her blood sugars were "pretty decent" this week but not as controlled as when she was on her established Rybelsus dose. She also said the pen works better than Rybelsus for her overall, but that switching means "you have to start basically all over again" on dosing. She copped to being anxious about self-injecting, admitting she read the directions "seven times" and still felt scared. That's more honesty than most health influencers offer.

She was also clear that the oral tablet caused significant nausea for her, which is consistent with what's documented in the clinical literature on Rybelsus tolerability. No wild claims here, no promises of a cure. This is a person narrating a lived medical experience in real time.

Does the science back this up?

Largely, yes. The dose-reset claim is accurate and worth understanding. When you switch formulations of semaglutide, you do restart at the lowest dose of the new formulation regardless of where you were on the previous one. This is standard clinical practice, not a quirk.

On nausea: a head-to-head pharmacokinetic comparison matters here. Rybelsus requires specific dosing conditions (fasting, limited water, 30-minute wait) and has lower bioavailability than the injectable, around 1% oral bioavailability according to Davies et al. (2021, Diabetes Care). That erratic absorption pattern, combined with GI exposure of the drug, likely explains why some patients report worse nausea on the oral form. The PIONEER 1 trial (Aroda et al., 2019, Diabetes Care) reported nausea rates of roughly 16-19% with oral semaglutide, and GI side effects were the primary reason for discontinuation. Subcutaneous delivery bypasses the gut wall, which for many patients means less direct GI irritation.

Her sense that glycemic control was better on her established Rybelsus dose is also plausible, not a sign the pen doesn't work. She was dose-optimized on Rybelsus and is now at the starting dose of the injectable. That's a pharmacology issue, not a formulation failure.

What did they get wrong (or right)?

She got more right than wrong. The framing that the pen "works better" than Rybelsus deserves some nuance, though. It's not that the injection is inherently superior in efficacy across the board. The PIONEER PLUS trial (Lingvay et al., 2023, The Lancet) showed that higher-dose oral semaglutide (25mg and 50mg) produced HbA1c and weight reductions comparable to injectable semaglutide. So "better" in her case is likely about tolerability and where she is in her titration, not a universal truth about the delivery method.

She didn't make any overclaims about weight loss, didn't suggest this is appropriate for people without diabetes, and didn't imply her experience generalizes to everyone. That's responsible. She's wearing a Dexcom G6, which suggests she's actively monitoring her glucose and working with a care team, not just freestyling her diabetes management on social media.

The needle anxiety she describes is well-documented and clinically relevant. Studies on injection-related anxiety in insulin and GLP-1 users show it's a real barrier to adherence. Her normalizing this experience is genuinely useful for other patients.

What should you actually know?

A few things this video touches on that deserve clearer context:

• Dose resets are real and intentional. Switching from any form of semaglutide to another requires restarting titration. This is not a flaw in the treatment, it's a safety protocol to minimize GI side effects during adjustment.
• Nausea differences between oral and injectable semaglutide are patient-specific. Some people tolerate Rybelsus fine. Others, like this creator, find the injectable easier on the gut. Neither experience is universal.
• Glycemic control during dose escalation will fluctuate. The fact that her numbers aren't as tight as on an established Rybelsus dose is expected. It doesn't mean the pen isn't working.
• Injection anxiety is common and shouldn't be dismissed. If you're starting an injectable GLP-1 and feeling scared, that's normal. Ask your provider or pharmacist to walk you through the injection technique in person.
• This is one person's experience with type 2 diabetes. GLP-1 medications are also used for weight management in people without diabetes, but the dosing, monitoring, and goals differ. Don't map her experience directly onto a different clinical context.